Conmed’s 2.2 percent convertible notes are funding the transaction, according to a June 13 news release. In2Bones’ portfolio includes implants, fracture systems and biologic products.
The deal was announced in May. The acquisition includes up to an additional $110 million in growth-based earnout payments over four years.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
